(Circulation. 2001;103:2805.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Institute for the Prevention of Cardiovascular Disease, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School (M.A.M., R.A.L.); the Department of Epidemiology (M.A.M., M.M.) and the Department of Health and Social Behavior (J.B.S.), Harvard School of Public Health; and the Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School (J.E.M.), Boston, Mass.
Correspondence to Murray A. Mittleman, MD, DrPH, Cardiovascular Division, Beth Israel Deaconess Medical Center, 1 Autumn Street, Fifth Floor, Boston, MA 02215. E-mail mmittlem{at}caregroup.harvard.edu
| Abstract |
|---|
|
|
|---|
Methods and ResultsIn the Determinants of Myocardial Infarction Onset Study, we interviewed 3882 patients (1258 women) with acute myocardial infarction an average of 4 days after infarction onset. We used the case-crossover study design to compare the reported use of marijuana in the hour preceding symptoms of myocardial infarction onset to its expected frequency using self-matched control data. Of the 3882 patients, 124 (3.2%) reported smoking marijuana in the prior year, 37 within 24 hours and 9 within 1 hour of myocardial infarction symptoms. Compared with nonusers, marijuana users were more likely to be men (94% versus 67%, P<0.001), current cigarette smokers (68% versus 32%, P<0.001), and obese (43% versus 32%, P=0.008). They were less likely to have a history of angina (12% versus 25%, P<0.001) or hypertension (30% versus 44%, P=0.002). The risk of myocardial infarction onset was elevated 4.8 times over baseline (95% confidence interval, 2.4 to 9.5) in the 60 minutes after marijuana use. The elevated risk rapidly decreased thereafter.
ConclusionsSmoking marijuana is a rare trigger of acute myocardial infarction. Understanding the mechanism through which marijuana causes infarction may provide insight into the triggering of myocardial infarction by this and other, more common stressors.
Key Words: cannabis myocardial infarction epidemiology cross-over studies
| Introduction |
|---|
|
|
|---|
Marijuana has several well-described effects on the cardiovascular system. For example, smoking marijuana is associated with a dose-dependent increase in the resting heart rate of 20% to 100%.2 3 4 5 6 7 8 9 10 Blood pressure is typically increased in the supine position,3 6 7 9 and postural hypotension, which is often symptomatic, is common. Overall, there is a net increase in myocardial oxygen demand with a decrease in oxygen supply, which is due in part to an increase in carboxyhemoglobin3 ; this results in a lower anginal threshold in patients with chronic stable angina.3 11 Furthermore, there are several reports of myocardial infarction occurring in close proximity to marijuana use in otherwise low-risk individuals.12 13 14
An Institute of Medicine report on marijuana and medicine released in 1999 noted that although the cardiovascular effects of marijuana do not seem to pose a health problem for healthy young users, they may present a serious problem for older subjects.15 The report also noted that any effect of marijuana use on cardiovascular disease could have a substantial impact on public health. The magnitude of the impact remains to be determined: long-term marijuana users from the late 1960s are now entering the years during which coronary arterial and cerebrovascular diseases become common. The report recommends that "studies to define the individual health risks of smoking marijuana should be conducted, particularly among populations in which marijuana use is prevalent."15
To evaluate whether marijuana is a trigger of the onset of an acute myocardial infarction, we collected data on marijuana use in 3882 patients (1258 women) who sustained an acute myocardial infarction and were interviewed for the Determinants of Myocardial Infarction Onset Study.16 17 In this multicenter, interview-based study, we used a case-crossover study design to compare the reported use of marijuana in the hour preceding the onset of myocardial infarction symptoms to its expected frequency using self-matched control data.
| Methods |
|---|
|
|
|---|
Interviewers identified eligible cases by reviewing coronary care unit admission logs and patients charts. For inclusion in the study, patients were required to meet all of the following criteria: at least one creatine kinase level above the upper limit of normal for the clinical laboratory performing the test, positive MB isoenzymes, an identifiable onset of pain or other symptoms typical of infarction, and the ability to complete a structured interview. The institutional review board at each participating center approved the protocol, and informed consent was obtained from each patient.
Detailed chart reviews and patient interviews were conducted by research personnel trained as previously described.16 17 18 Data were collected on standard demographic variables and risk factors for coronary artery disease. The interview identified the time, place, and quality of myocardial infarction pain and other symptoms, as well as the timing and estimated usual frequency of exposure to potential triggers of myocardial infarction onset during the prior year. In addition, patients were asked if they had smoked marijuana in the year preceding their infarction. Patients who reported smoking marijuana were also asked to report the last time that they had smoked marijuana and their usual frequency of smoking marijuana over the prior year. Patients were also asked to report the timing of exposure to marijuana and other potential triggers for each of the 26 hours preceding the onset of their symptoms.
Study Design
The design of the Onset Study has been described in
detail
elsewhere.16 17 18 19 20 21
In brief, we used a case-crossover study
design16 19 20 22
to assess the change in the risk of acute myocardial infarction during
a brief "hazard period" after exposure to marijuana and other
potential triggers of myocardial infarction onset. An important feature
of the case-crossover design is that control information for each
patient is based on his or her own past exposure
experience.16 19 20
Self-matching results in freedom from confounding by risk factors that
are stable over time but often differ between study
subjects.
Marijuana use in the hazard period, the 1-hour period immediately preceding the onset of myocardial infarction symptoms, was compared with its expected frequency based on control data obtained from the patients. We used the usual frequency of marijuana use over the year before myocardial infarction to estimate its expected frequency in an average 1-hour period in this patient population.
Statistical Analysis
The analysis of case-crossover data is an
application of standard methods for stratified data
analysis.19 20 23 24
In this analysis, the stratifying variable is the
individual patient, as in a crossover experiment. The ratio of the
observed exposure frequency in the hazard period to the expected
frequency (from the control information) was used to calculate
estimates of the odds ratio as a measure of relative
risk.16 19 20
The amount of person-time exposed to marijuana was estimated by
multiplying the reported usual annual frequency of exposure by the
duration of its hypothesized physiological effect
(1 hour). Unexposed person-time was then calculated by subtracting the
exposed person-time in hours from the number of hours in a year. The
data were analyzed using methods for cohort studies with sparse
data in each
stratum.19 20 25
Sensitivity Analyses
To evaluate whether exposure to other triggering
behaviors could account for the observed effect of smoking marijuana,
we conducted a sensitivity analysis excluding patients who
smoked marijuana and engaged in other potentially triggering activities
in the hour preceding their infarction.
In another sensitivity analysis, we evaluated the timing of marijuana use among the patients who reported smoking it in the 24 hours before the onset of their infarction symptoms. In this analysis, we compared the number of patients who reported smoking marijuana in the hour before symptom onset to the expected number that would arise if smoking marijuana was unrelated to myocardial infarction onset and the frequency of smoking marijuana was evenly distributed over the prior day.
| Results |
|---|
|
|
|---|
|
Table 2
shows the distribution of the usual frequency of
marijuana use among the 124 patients who reported smoking marijuana in
the year before their myocardial infarction. The majority of patients
who smoked marijuana reported using it at least once per month
(67.7%), with 41.2% smoking marijuana at least weekly.
|
Of the 124 patients who reported smoking marijuana, 37 reported smoking it within 24 hours of myocardial infarction onset and 9 reported use within 1 hour of myocardial infarction symptom onset. In addition to these 9 patients, 3 patients reported using marijuana between 60 and 120 minutes before the onset of symptoms. Of the 37 patients who reported smoking marijuana within 24 hours of myocardial infarction symptoms, only 5 reported smoking it once per month or less, and 28 (76%) reported smoking it at least weekly. Similarly, 7 of the 9 patients (78%) who reported smoking marijuana within 1 hour of symptom onset reported smoking it at least once per week.
On the basis of a case-crossover analysis that
controlled for differences between patients, we found that within 1
hour after smoking marijuana, the risk of myocardial infarction onset
was elevated 4.8-fold (95% confidence interval, 2.9 to 9.5;
P<0.001) compared with periods
of nonuse. In the second hour after smoking, the relative risk was 1.7
(95% confidence interval, 0.6 to 5.1;
P=0.34), suggesting a rapid
decline in the cardiac effects of marijuana
(Figure
).
|
A total of 3 patients who smoked marijuana in the hour before their infarction also engaged in other triggering behaviors that hour. One patient reported using cocaine in addition to smoking marijuana, another reported sexual intercourse, and a third patient reported both sexual intercourse and cocaine use. None of the patients who smoked marijuana in the period 1 to 2 hours before their myocardial infarction reported exposure to other known triggers in that hour. A sensitivity analysis excluding these 3 patients resulted in a relative risk of 3.2 (95% confidence interval, 1.4 to 7.3; P=0.007) for smoking marijuana in the absence of other potential triggers of myocardial infarction.
In another sensitivity analysis, we evaluated the timing of marijuana use among the 37 patients who reported smoking it in the 24 hours before the onset of their infarction symptoms. If smoking marijuana was unrelated to myocardial infarction onset, we would expect these 37 cases to be evenly distributed over the 24-hour period. This sensitivity analysis resulted in a relative risk of 5.8 (95% confidence interval, 2.8 to 12.1).
Because of the small number of exposed cases, we were unable to evaluate whether the risk of having a myocardial infarction associated with smoking marijuana differed in subsets of patients.
| Discussion |
|---|
|
|
|---|
The elevation in the risk of myocardial infarction in the hour after marijuana use that we observed was much smaller than the risk previously reported for cocaine,17 which unlike marijuana is associated with a marked increase in sympathetic stimulation. We have previously reported that cocaine is associated with a nearly 24-fold increase in the risk of myocardial infarction onset in the hour after use.17
Biological Effects of Marijuana
The effects of cannabinoids are primarily mediated by
the activation of cannabinoid receptors, which are present in a
variety of tissues including the brain (basal ganglia, substantia nigra
pars reticulata, entopeduncular nucleus, globus pallidus, putamen,
cerebellum, hippocampus, and cerebral cortex) and cells of the immune
system, spleen, blood vessels, and the
heart.15 26 The
cannabinoid receptors are part of the family of G proteincoupled
receptors. Two main subtypes of cannabinoid receptors have been
identified and cloned (CB1 and CB2), and a naturally occurring agonist,
anandamide, has been identified. In addition to these receptors, Jarai
and colleagues26 recently
identified cannabinoid-induced mesenteric vasodilatation through an
endothelial site distinct from CB1 or CB2
receptors.
However, the biological effects of smoked marijuana are complex. In addition to the effects of delta-9-tetrahydrocannabinol and other cannabinoids, smoking marijuana is also associated with exposure to particulates and gaseous material arising from the combustion of plant products. In addition, it is not uncommon for marijuana and, more commonly, other cannabinoids such as hashish to be mixed with tobacco.
Several effects of smoked marijuana on the cardiovascular system have been well described. For example, smoking marijuana is associated with a dose-dependent increase in heart rate.2 3 4 5 6 7 8 9 10 Although there is much interindividual variability, typical increases in heart rate associated with a single marijuana cigarette range from 20% to 100%, with the peak in heart rate occurring 10 to 30 minutes after beginning to smoke.2 4 6 7 8 In addition, most subjects experience an increase in blood pressure, particularly when supine.3 6 7 9 Postural hypotension after smoking marijuana is not uncommon.5 9 27 Tolerance to the hemodynamic effects of marijuana can occur with frequent repeated use.27 28
In addition to the hemodynamic effects, smoked marijuana is associated with an increase in carboxyhemoglobin, resulting in decreased oxygen-carrying capacity.3 5 11 Whether marijuana affects the hemostatic balance is unclear. Marijuana may increase factor VII activity; however, there are mixed results in terms of the effects of smoked marijuana on platelet function.29 Thus, taken together, smoking marijuana is associated with an increase in myocardial oxygen demand and a concomitant decrease in oxygen supply.
Aronow and Cassidy3 11 demonstrated that among patients with chronic stable angina, the anginal threshold is acutely diminished after smoking a single marijuana cigarette. In particular, the exercise time to angina was decreased by an average of 48% after smoking a single marijuana cigarette, compared with an 8.6% decrease after smoking a marijuana placebo (marijuana cigarette with no delta-9-tetrahydrocannabinol) and a 23% decrease after smoking a high nicotine tobacco cigarette.3 11
Thus, some marijuana-associated infarctions may be caused by a myocardial oxygen supply that is inadequate to cope with the increased oxygen demands that occur as result of smoking marijuana. However, the culprit lesion in a majority of myocardial infarctions occurs at the site of a disrupted atherosclerotic plaque.30 31 A proposed mechanism for the triggering of myocardial infarction is that onset occurs when a vulnerable, but not necessarily stenotic, atherosclerotic plaque is disrupted in response to hemodynamic stresses; thereafter, hemostatic and vasoconstrictive forces determine whether the resultant thrombus becomes occlusive.32 33 Whether the direct or indirect hemodynamic effects of marijuana are sufficient to cause plaque disruption is speculative, because there are no direct studies of this phenomenon available in the literature.
Limitations
The present study has several potential
limitations. Because the data are based on patient self-report, some
misclassification of exposure is likely to have occurred. For example,
patients may be reluctant to report that they had used marijuana before
their myocardial infarction. The effect of such a bias would reduce the
magnitude of the estimated relative risk. In an effort to minimize such
reporting bias and to maintain patient confidentiality, efforts were
made to ensure the patients privacy during the interview.
Furthermore, to obtain comparable reporting of marijuana smoking for
all of the hourly intervals during the day preceding the infarction,
patients were not informed of the duration of the hypothesized hazard
period.
There is a possibility of bias caused by differential survival of cases who had their myocardial infarction triggered by different mechanisms. For example, if patients whose infarctions were triggered by marijuana were more likely to die than those whose infarctions were unrelated to marijuana, then the apparent relative risk may be underestimated.
However, it is possible that patients under-report long-term use of marijuana because of the social stigma attached to it, but they may be relatively accurate about its use on the day of their myocardial infarction because of potential clinical benefit. This may result in an overestimate of the relative risk. However, the sensitivity analysis restricted to the 37 patients who reported smoking marijuana within 24 hours of the onset of myocardial infarction symptoms resulted in a relative risk of 5.8, which is similar to the result based on all patients who reported smoking marijuana in the prior year.
In traditional epidemiological studies of coronary heart disease, confounding by differences in risk factors between individuals is a major threat to validity. A strength of the case-crossover design used in this study is that self-matching ensures that within strata, there is no variability in traditional chronic risk factors for coronary heart disease. Thus, by design, confounding by all traditional chronic risk factors for coronary heart disease, whether measured or unmeasured, is controlled for in the analysis.19 24
A limitation of the case-crossover design used in this study
is that, like case-control studies, the absolute risk of myocardial
infarction onset cannot be directly estimated from the data. However,
an estimate of the baseline risk can be made using other data sources.
For example, on the basis of the Framingham Heart Study risk
equation,34 35
the baseline risk of acute myocardial infarction for a typical
marijuana user in this study (44-year-old male smoker with average
levels of other risk factors) is between 1 and 1.5 per million per
hour. Thus, in the hour after marijuana use, the absolute risk would
increase to
7 per million per hour. For a daily user of marijuana,
the risk would accumulate over the course of time, leading to an annual
excess risk of an acute cardiovascular event of
1.5% to 3% per year. Furthermore, for high-risk patients with
either multiple risk factors or established coronary artery
disease, the risk may be substantially higher.
In summary, smoking marijuana is a rare trigger of acute myocardial infarction and may pose a health risk to patients with established coronary artery disease and perhaps to individuals with multiple coronary risk factors. Understanding the mechanism by which marijuana causes infarction may provide insight into the triggering of myocardial infarction by this and other, more common stressors.
| Acknowledgments |
|---|
Received September 5, 2000; revision received April 2, 2001; accepted April 3, 2001.
| References |
|---|
|
|
|---|
2.
Renault PF,
Schuster CR, Heinrich R, et al. Marihuana. standardized smoke
administration and dose effect curves on heart rate in humans.
Science. 1971;174:589591.
3. Aronow WS, Cassidy J. Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med. 1974;291:6567.
4. Clark SC, Greene C, Karr GW, et al. Cardiovascular effects of marihuana in man. Can J Physiol Pharmacol. 1974;52:706719.[Medline] [Order article via Infotrieve]
5. Hollister LE. Health aspects of cannabis. Pharmacol Rev. 1986;38:120.[Abstract]
6. Johnson S, Domino EF. Some cardiovascular effects of marihuana smoking in normal volunteers. Clin Pharmacol Ther. 1971;12:762768.[Medline] [Order article via Infotrieve]
7. Roth WT, Tinkleinberg JR, Kopell BS, et al. Continuous electrocardiographic monitoring during marihuana intoxication. Clin Pharmacol Ther. 1973;14:533540.[Medline] [Order article via Infotrieve]
8. Beaconsfield P, Ginsburg J, Rainsbury R. Marihuana smoking: cardiovascular effects in man and possible mechanisms. N Engl J Med. 1972;287:209212.
9. Weiss JL, Watanabe AM, Lemberger L, et al. Cardiovascular effects of delta-9-tetrahydrocannabinol in man. Clin Pharmacol Ther. 1972;13:671684.[Medline] [Order article via Infotrieve]
10. Hollister LE. Cannabis: 1988. Acta Psychiatr Scand Suppl. 1988;345:108118.[Medline] [Order article via Infotrieve]
11. Aronow WS, Cassidy J. Effect of smoking marihuana and of a high-nicotine cigarette on angina pectoris. Clin Pharmacol Ther. 1975;17:549554.[Medline] [Order article via Infotrieve]
12. Charles R, Holt S, Kirkham N. Myocardial infarction and marijuana. Clin Toxicol. 1979;14:433438.[Medline] [Order article via Infotrieve]
13.
Collins JS,
Higginson JD, Boyle DM, et al. Myocardial infarction during marijuana
smoking in a young female. Eur Heart
J. 1985;6:637638.
14. Pearl W, Choi YS. Marijuana as a cause of myocardial infarction. Int J Cardiol. 1992;34:353.[Medline] [Order article via Infotrieve]
15. Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press; 1999.
16.
Mittleman MA,
Maclure M, Tofler GH, et al. Triggering of acute myocardial infarction
by heavy exertion: protection against triggering by regular exertion.
N Engl J Med. 1993;329:16771683.
17.
Mittleman MA,
Mintzer D, Maclure M, et al. Triggering of myocardial infarction by
cocaine. Circulation. 1999;99:27372741.
18.
Mittleman MA,
Maclure M, Sherwood JB, et al. Triggering of myocardial infarction by
episodes of anger. Circulation. 1995;92:17201725.
19.
Maclure M. The
case-crossover design: a method for studying transient effects on the
risk of acute events. Am J
Epidemiol. 1991;133:144153.
20.
Mittleman MA,
Maclure M, Robins JM. Control sampling strategies for case-crossover
studies: an assessment of relative efficiency.
Am J Epidemiol. 1995;142:9198.
21.
Muller JE,
Mittleman MA, Maclure M, et al. Triggering myocardial infarction by
sexual activity: low absolute risk and prevention by regular exertion.
JAMA. 1996;275:14051409.
22. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health. 2000;21:193221.[Medline] [Order article via Infotrieve]
23. Rothman KJ. Modern Epidemiology. Boston, Mass: Little, Brown and Company; 1986.
24.
Wacholder S,
Silverman DT, McLaughlin JK, et al. Selection of controls in
case-control studies. Am J
Epidemiol. 1992;135:10191028.
25. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985;41:5568.[Medline] [Order article via Infotrieve]
26.
Jarai Z, Wagner
JA, Varga K, et al. Cannabinoid-induced mesenteric vasodilation through
an endothelial site distinct from CB1 or CB2 receptors.
Proc Natl Acad Sci
U S A. 1999;96:1413614141.
27. Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther. 1975;18:287297.[Medline] [Order article via Infotrieve]
28. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci. 1976;282:221239.
29. Heiden D, Rodvien R, Jones R, et al. Effect of oral delta-9-tetrahydrocannabinol on coagulation. Thromb Res. 1980;17:885889.[Medline] [Order article via Infotrieve]
30.
Davies MJ,
Thomas AC. Plaque fissuring: the cause of acute myocardial
infarction, sudden ischemic death, and crescendo angina.
Br Heart J. 1985;53:363373.
31.
Fuster V, Lewis
A. Conner memorial lecture: mechanisms leading to myocardial
infarction: insights from studies of vascular biology.
Circulation. 1994;90:21262146.
32.
Muller JE, Tofler
GH, Stone PH. Circadian variation and triggers of onset of acute
cardiovascular disease.
Circulation. 1989;79:733743.
33. Muller JE, Abela GS, Nesto RW, et al. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol. 1994;23:809813.[Abstract]
34. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J. 1993;121:293298.
35.
Anderson
KM, Wilson PW, Odell PM, et al. An updated coronary risk
profile: a statement for health professionals.
Circulation. 1991;83:356362.
This article has been cited by other articles:
![]() |
M. Pujazon-Zazik and M. J. Park Marijuana: Use Among Young Males and Health Outcomes American Journal of Men's Health, September 1, 2009; 3(3): 265 - 274. [Abstract] [PDF] |
||||
![]() |
M. J. Seamon, J. A. Fass, M. Maniscalco-Feichtl, and N. A. Abu-Shraie Medical marijuana and the developing role of the pharmacist Am. J. Health Syst. Pharm., May 15, 2007; 64(10): 1037 - 1044. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Ornato, J. E. Muller, E. S. Froelicher, and R. A. Kloner Task Force II: Indirect and Secondary Cardiovascular Effects of Biological Terrorism Agents and Diseases J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1389 - 1397. [Full Text] [PDF] |
||||
![]() |
G. H. Tofler and J. E. Muller Triggering of Acute Cardiovascular Disease and Potential Preventive Strategies Circulation, October 24, 2006; 114(17): 1863 - 1872. [Full Text] [PDF] |
||||
![]() |
A Zeka, A Zanobetti, and J Schwartz Short term effects of particulate matter on cause specific mortality: effects of lags and modification by city characteristics Occup. Environ. Med., October 1, 2005; 62(10): 718 - 725. [Abstract] [Full Text] [PDF] |
||||
![]() |
B A C Fisher, A Ghuran, V Vadamalai, and T F Antonios Cardiovascular complications induced by cannabis smoking: a case report and review of the literature Emerg. Med. J., September 1, 2005; 22(9): 679 - 680. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. de Jong, F. K. Engels, R. H.J. Mathijssen, L. van Zuylen, J. Verweij, R. P.H. Peters, and A. Sparreboom Medicinal Cannabis in Oncology Practice: Still a Bridge Too Far? J. Clin. Oncol., May 1, 2005; 23(13): 2886 - 2891. [Full Text] [PDF] |
||||
![]() |
I Mateo, A Pinedo, M Gomez-Beldarrain, J M Basterretxea, and J C Garcia-Monco Recurrent stroke associated with cannabis use J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 435 - 437. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Moller, T. Theorell, U. de Faire, A. Ahlbom, and J. Hallqvist Work related stressful life events and the risk of myocardial infarction. Case-control and case-crossover analyses within the Stockholm heart epidemiology programme (SHEEP) J Epidemiol Community Health, January 1, 2005; 59(1): 23 - 30. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Peters, S. von Klot, M. Heier, I. Trentinaglia, A. Hormann, H. E. Wichmann, H. Lowel, and the Cooperative Health Research in the Region of A Exposure to Traffic and the Onset of Myocardial Infarction N. Engl. J. Med., October 21, 2004; 351(17): 1721 - 1730. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Deusch, H. G. Kress, B. Kraft, and S. A. Kozek-Langenecker The Procoagulatory Effects of Delta-9-Tetrahydrocannabinol in Human Platelets Anesth. Analg., October 1, 2004; 99(4): 1127 - 1130. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Compton, B. F. Grant, J. D. Colliver, M. D. Glantz, and F. S. Stinson Prevalence of Marijuana Use Disorders in the United States: 1991-1992 and 2001-2002 JAMA, May 5, 2004; 291(17): 2114 - 2121. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Varadhan and C. E. Frangakis Revealing and Addressing Length Bias and Heterogeneous Effects in Frequency Case-Crossover Studies Am. J. Epidemiol., March 15, 2004; 159(6): 596 - 602. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sidney Comparing cannabis with tobacco--again BMJ, September 20, 2003; 327(7416): 635 - 636. [Full Text] [PDF] |
||||
![]() |
J. A Henry, W. L G Oldfield, and O. M. Kon Comparing cannabis with tobacco BMJ, May 3, 2003; 326(7396): 942 - 943. [Full Text] [PDF] |
||||
![]() |
P. K. Shah Mechanisms of plaque vulnerability and rupture J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 15S - 22S. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Ghuran, L R van der Wieken, and J Nolan Cardiovascular complications of recreational drugs BMJ, September 1, 2001; 323(7311): 464 - 466. [Full Text] [PDF] |
||||
![]() |
Marijuana Use May Be Temporally Related to MI Journal Watch Cardiology, August 31, 2001; 2001(831): 11 - 11. [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |